BBLG · Bone Biologics Corp

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice,vests and becomes exercisable immediately.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vesting and becoming exercisable in four equal installments on 12/17/24, 3/19/25, 6/19/25 and 9/17/25.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable on the date of the next annual meeting of the stockholders of the Company following the grant date.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable quarterly through the date of the next annual meeting of stockholders of the Company.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable quarterly through the date of the next annual meeting of stockholders of the Company.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable quarterly through the date of the next annual meeting of stockholders of the Company.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, 2,003 options are immediately exercisable with the remaining 6,003 options vesting and becoming exercisable in three equal installments on 3/12/2024, 6/12/2024, and 9/12/2024.

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable on the date of the next annual meeting of the stockholders of the Company following the grant date.

Vests quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

Vests quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

Vests quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6799 to $0.6898, inclusive. Mr. Frelick undertakes to provide Bone Biologics Corporation, any security holder of Bone Biologics Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Includes 104 shares of vested restricted stock that were inadvertently reported in Table II at the time of grant.

On March 27, 2023, Hankey Capital LLC transferred an aggregate of 7,043,801 shares and 476,190 shares issuable upon exercise of warrants of the Company as follows: a. Don Hankey Trust, Related Party, 4,153,065 shares, 280,764 warrants b. Knight Services, Inc, Related Party, 77,681 shares, 5,252 warrants c. Knight Insurance Company, Ltd., Related Party, 1,466,603 shares, 99,148 warrants d. Knightbrook Insurance Company, Related Party, 285,438 shares, 19,297 warrants e. Knight Specialty Insurance Company, Related Party, 560,877 shares, 37,918 warrants f. Unrelated Parties, 500,137 shares, 33,811 warrants

On March 27, 2023, Hankey Capital LLC transferred an aggregate of 7,043,801 shares and 476,190 shares issuable upon exercise of warrants of the Company as follows: a. Don Hankey Trust, Related Party, 4,153,065 shares, 280,764 warrants b. Knight Services, Inc, Related Party, 77,681 shares, 5,252 warrants c. Knight Insurance Company, Ltd., Related Party, 1,466,603 shares, 99,148 warrants d. Knightbrook Insurance Company, Related Party, 285,438 shares, 19,297 warrants e. Knight Specialty Insurance Company, Related Party, 560,877 shares, 37,918 warrants f. Unrelated Parties, 500,137 shares, 33,811 warrants

On March 27, 2023, Hankey Capital LLC transferred an aggregate of 7,043,801 shares and 476,190 shares issuable upon exercise of warrants of the Company as follows: a. Don Hankey Trust, Related Party, 4,153,065 shares, 280,764 warrants b. Knight Services, Inc, Related Party, 77,681 shares, 5,252 warrants c. Knight Insurance Company, Ltd., Related Party, 1,466,603 shares, 99,148 warrants d. Knightbrook Insurance Company, Related Party, 285,438 shares, 19,297 warrants e. Knight Specialty Insurance Company, Related Party, 560,877 shares, 37,918 warrants f. Unrelated Parties, 500,137 shares, 33,811 warrants

On March 27, 2023, Hankey Capital LLC transferred an aggregate of 7,043,801 shares and 476,190 shares issuable upon exercise of warrants of the Company as follows: a. Don Hankey Trust, Related Party, 4,153,065 shares, 280,764 warrants b. Knight Services, Inc, Related Party, 77,681 shares, 5,252 warrants c. Knight Insurance Company, Ltd., Related Party, 1,466,603 shares, 99,148 warrants d. Knightbrook Insurance Company, Related Party, 285,438 shares, 19,297 warrants e. Knight Specialty Insurance Company, Related Party, 560,877 shares, 37,918 warrants f. Unrelated Parties, 500,137 shares, 33,811 warrants

On March 27, 2023, Hankey Capital LLC transferred an aggregate of 7,043,801 shares and 476,190 shares issuable upon exercise of warrants of the Company as follows: a. Don Hankey Trust, Related Party, 4,153,065 shares, 280,764 warrants b. Knight Services, Inc, Related Party, 77,681 shares, 5,252 warrants c. Knight Insurance Company, Ltd., Related Party, 1,466,603 shares, 99,148 warrants d. Knightbrook Insurance Company, Related Party, 285,438 shares, 19,297 warrants e. Knight Specialty Insurance Company, Related Party, 560,877 shares, 37,918 warrants f. Unrelated Parties, 500,137 shares, 33,811 warrants

On March 27, 2023, Hankey Capital LLC transferred an aggregate of 7,043,801 shares and 476,190 shares issuable upon exercise of warrants of the Company as follows: a. Don Hankey Trust, Related Party, 4,153,065 shares, 280,764 warrants b. Knight Services, Inc, Related Party, 77,681 shares, 5,252 warrants c. Knight Insurance Company, Ltd., Related Party, 1,466,603 shares, 99,148 warrants d. Knightbrook Insurance Company, Related Party, 285,438 shares, 19,297 warrants e. Knight Specialty Insurance Company, Related Party, 560,877 shares, 37,918 warrants f. Unrelated Parties, 500,137 shares, 33,811 warrants

On March 27, 2023, Hankey Capital LLC transferred an aggregate of 7,043,801 shares and 476,190 shares issuable upon exercise of warrants of the Company as follows: a. Don Hankey Trust, Related Party, 4,153,065 shares, 280,764 warrants b. Knight Services, Inc, Related Party, 77,681 shares, 5,252 warrants c. Knight Insurance Company, Ltd., Related Party, 1,466,603 shares, 99,148 warrants d. Knightbrook Insurance Company, Related Party, 285,438 shares, 19,297 warrants e. Knight Specialty Insurance Company, Related Party, 560,877 shares, 37,918 warrants f. Unrelated Parties, 500,137 shares, 33,811 warrants

Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

Represents shares purchased in the Issuer's public offering of units, with each unit consisting of one share of Common Stock and one Warrant. The allocation of a unit is $5.24 for a common share, and $0.01 for a warrant.

Represents cancelation of collateral shares issued to secure the debt.

Represents shares purchased in the Issuer's public offering of units, with each unit consisting of one share of Common Stock and one Warrant. The allocation of a unit is $5.24 for a common share, and $0.01 for a warrant.

Represents shares issued upon conversion of debt at a conversion rate of $2.50 per share.